Schrödinger, Inc.

Schrödinger, Inc. is a leading technology company that focuses on advancing the field of computational biochemistry and drug discovery. Founded in 1990, the company has developed a unique platform that integrates physics-based simulations with machine learning to accelerate the process of drug development.

With a commitment to innovation, Schrödinger aims to transform the way new medicines are discovered and developed. The company’s software solutions are used by pharmaceutical and biotechnology companies worldwide to predict the properties of molecules and optimize their designs.

Schrödinger’s core activities include:

• Computational Chemistry: Utilizing advanced algorithms to simulate molecular interactions.
• Drug Discovery: Streamlining the identification and optimization of potential drug candidates.
• Material Science: Applying its technology to develop new materials with desirable properties.

The company is headquartered in New York City but has a significant presence in the UK, where it collaborates with various research institutions and industry partners. Schrödinger is dedicated to fostering a culture of scientific excellence and collaboration, ensuring that its team of experts remains at the forefront of technological advancements.

Through its innovative approach, Schrödinger not only enhances the efficiency of drug discovery but also contributes to the overall improvement of healthcare outcomes. The company envisions a future where every patient has access to effective and personalized treatments, made possible through cutting-edge technology.